ZTALMY
ZTALMY (ganaxolone) is a neuroactive steroid indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. It is approved for use in pediatric and adult patients 2 years of age and older. This medication provides a therapeutic option specifically for managing the seizure activity linked to this genetic condition.
How ZTALMY Works
While the precise mechanism of ganaxolone is unknown, its therapeutic effects are thought to result from its activity in the central nervous system. The drug acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA A) receptor. By modulating these receptors, the medication produces anticonvulsant effects to help manage seizures.
Details
- Status
- Prescription
- First Approved
- 2022-03-18
- Routes
- ORAL
- Dosage Forms
- SUSPENSION
ZTALMY Approval History
What ZTALMY Treats
2 indicationsZTALMY is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Seizures
- Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
Drugs Similar to ZTALMY
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ZTALMY FDA Label Details
ProIndications & Usage
FDA Label (PDF)ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ZTALMY is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.
ZTALMY Patents & Exclusivity
Patents (11 active)
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.